JNJJanssen Research & Development, LLCSigning up patients
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Myasthenia Gravis
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 115 (planned)
- Started
- Jan 5, 2026
- Main results expected
- Sep 28, 2027
- Fully finished
- Jan 29, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Arms 1 and 2: Averaged Mean Percent Change from Baseline in Total Immunoglobulin G (IgG) Levels Over Weeks 8, 10 and 12
Measured over: Baseline, Weeks 8, 10 and 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07217587 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC